I Leader della Finanza

Ultime notizieSocietÓMercatiEconomia & ForexMaterie PrimeTassiLeader della FinanzaPro. della FinanzaCalendarioSettori 
HomeTutte le notizieLe notizie pi¨ letteBiografie dei Leader della finanza
Riassunto 
Paul A. Hopper is an entrepreneur and businessperson who founded 7 companies, notably: Imugene Ltd., Prescient Therapeutics Ltd. and Chimeric Therapeutics Ltd. (Australia) and who has been the head of 14 different companies. Presently, Paul A. Hopper is Executive Chairman of Imugene Ltd. (which he founded in 2012), Chairman for Vaxinia Pty Ltd. (a subsidiary of Imugene Ltd.), Executive Chairman at Arovella Therapeutics Ltd., Executive Chairman at Chimeric Therapeutics Ltd. (Australia) (which he founded in 2020) and Executive Chairman for Radiopharm Theranostics Ltd. Paul A. Hopper is also on the board of Biolife Science Ltd. and Managing Director at Cappello Group, Inc., MD, Head-Life Sciences & Biotechnology Group at Cappello Global LLC and Member of Pacific Council on International Policy.

He previously was Executive Chairman of CAQ Holdings Ltd., Executive Chairman for Botanix Pharmaceuticals Ltd., Independent Director at Scopus Biopharma, Inc. and Executive Chairman of Bioscience Oncology Pty Ltd. (a subsidiary of Scopus Biopharma, Inc.), Managing Director at Alpha Healthcare Ltd. (he founded the company), Executive Chairman for Viralytics Pty Ltd., President for Innovate Oncology, Inc., Managing Director at The Merchants Bank of New York, Managing Director at Avantogen Ltd., Chief Operating Officer & Director at Acuvax Ltd., Chairman-California Chapter at American Australian Association, Non-Executive Director at Prescient Therapeutics Ltd. and Lead Director at Polynoma LLC.

Paul A. Hopper received an undergraduate degree from The University of New South Wales.


Posti e reponsabilitÓ di Paul A. Hopper 
NomeTitolo Da
Imugene Limited
(Biotecnologia)
Executive Chairman 2014
Chimeric Therapeutics Limited
(Biotecnologia)
Executive Chairman 2020
Radiopharm Theranostics Limited
(Prodotti farmaceutici)
Executive Chairman -
Arovella Therapeutics Limited
(Biotecnologia)
Executive Chairman 2019
Vaxinia Pty Ltd. Chairman -
Biolife Science Ltd. Director -
Cappello Group, Inc. Managing Director 2015
Cappello Global LLC MD, Head-Life Sciences & Biotechnology Group 2014
Pacific Council on International Policy Member -


Participazioni di Paul A. Hopper 
NomeAzioni%Valorizzazione
Imugene Limited (IMU)
(Biotecnologia)
317 131 6485,42%44 360 375 USD
Chimeric Therapeutics Limited (CHM)
(Biotecnologia)
84 035 13020,0%6 932 898 USD
Scopus BioPharma Inc. (SCPS)
(Biotecnologia)
1 400 0006,64%551 600 USD
Radiopharm Theranostics Limited (RAD)
(Prodotti farmaceutici)
400 0000,16%55 952 USD


Paul A. Hopper: network personale 
Le notizie pi¨ lette 
22/06ELON MUSK: Musk dice che le nuove fabbriche di automobili di Tesla 'perdono miliardi di dollari'.
MR
15/06ELON MUSK: Elon Musk ricorre in appello contro la decisione relativa all'accordo con la SEC per i post su Twitter
MR
23/06MARK MILLER: Colonna - Vuole fare qualcosa per i suoi risparmi pensionistici in difficoltà? Non
MR
14/06ELON MUSK: Musk parteciperà all'incontro Q&A del personale di Twitter per la prima volta da quando ha lanciato l'offerta.
MR
22/06TREVOR MILTON: Il fondatore di Nikola, Trevor Milton, affronta una nuova accusa di frode
MR
13/06BENEDETTO VIGNA: Vigna illustrerà il percorso della Ferrari nell'era dei veicoli elettrici
MR
21/06ELON MUSK: Musk dice che ci sono ancora alcune questioni irrisolte con l'offerta di Twitter.
MR
16/06ELON MUSK: Elon Musk dovrebbe ribadire il desiderio di possedere Twitter durante l'incontro di giovedì - WSJ
MR
15/06CARLO MESSINA: Italia non deve rivolgersi a Bce per sostenere debito pubblico - Messina (Intesa)
RE
22/06MARK TUCKER: Glass Lewis raccomanda agli investitori di Aerojet di appoggiare l'amministratore delegato nella contesa per le deleghe.
MR
Altre news


© 2022 People and Ownership :   
Paul A. Hopper : connessioni